The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

Amid the growing burden of Non-Communicable Diseases (NCDs), India’s Union Ayush Ministry has launched yoga protocols that will target vulnerable groups with diabetes, high blood pressure, and asthma.

The “Yoga Protocol for Non-Communicable Diseases (NCDs) and Target Groups” is a significant push towards reshaping the country’s healthcare narrative from treatment to prevention, PTI reported.

NCDs such as diabetes, hypertension, cardiovascular ailments, chronic respiratory conditions, and mental health disorders are increasing significantly in the country. These also account for about 60 percent of all deaths in the country, signaling a clear need to focus on preventing the lifestyle-driven illnesses.

Also Read: IPL 2026: Rohit Sharma's Transformation Impresses Nita Ambani; Fitness Secrets Revealed

Prataprao Jadhav, Union Minister of State (Independent Charge) for Ayush, noted that prevention of these conditions is important for the better health of the nation, and yoga is India’s answer to the rising burden of lifestyle diseases.

“Through these evidence-based protocols, we are empowering every citizen to take charge of their own health and well-being in a simple, accessible, and sustainable manner. By integrating yoga into daily life, we aim to shift the focus from illness to wellness, reducing long-term healthcare pressures,” he said.

“This initiative reflects our commitment to building a healthier nation through holistic, preventive, and people-centric approaches rooted in India’s rich traditional knowledge,” the minister added.

What Are The Protocols?

It is part of the Yoga Mahotsav 2026, launched earlier this month by Union Ayush Minister Prataprao Jadhav, developed by the World Health Organization (WHO).

The protocols are designed as structured, evidence-based modules that integrate Yogic practices into daily life in a simple, accessible, and scalable manner.

The initiative has specific yoga interventions curated for major health conditions such as:

• diabetes — improving metabolic balance and glycemic control;
• hypertension — calming the nervous system and regulating blood pressure;
• bronchial asthma — strengthening respiratory capacity and improving lung function
• emotional well-being — breathing and meditation aimed at reducing stress, anxiety, and depression.

Further, it includes

• playful yoga modules for young children
• mental health-focused routines for adolescents,
• mobility-enhancing practices for the elderly
• specialized guidelines for women and pregnant mothers.

Yoga 365

The Ministry of Ayush has also launched Yoga 365 — a nationwide campaign to make yoga an integral part of citizens' daily lives — that goes beyond the International Day of Yoga (IDY), marked annually on June 21 worldwide.

According to the National Sample Survey (NSS), awareness of traditional systems like yoga stands at 95 percent in rural India and 96 percent in urban India.

The NSS also found that in around 1.1 crore households in rural India and around 1.4 crore households in urban India, at least one household member regularly practices yoga.

The Yoga 365 campaign aims to

• mobilize communities through mission-mode outreach,
• promote behavior change,
• integrate yoga into diverse spaces—from schools and offices to neighborhood groups and digital platforms.

The Morarji Desai National Institute of Yoga, under the Ministry of Ayush, has also signed a Memorandum of Understanding with the wellness platform Habuild to offer free daily online yoga sessions.

The COVID-19 BA.3.2 strain, nicknamed Cicada Variant, is spreading rapidly in the US, raising the possibility of becoming the dominant strain in the country, according to experts.

The US Centers for Disease Control and Prevention (CDC), in its latest report, has raised concerns about BA.3.2 — a highly mutated variant of COVID.

BA.3.2 has already been reported in at least 23 countries, including 25 states in America, as per the report. It has also been detected in 132 wastewater samples from Massachusetts.

The 25 states include California, Connecticut, Florida, Hawaii, Idaho, Illinois, Louisiana, Maine, Michigan, Maryland, Massachusetts, Missouri, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Virginia, and Wyoming.

"Cicada can become the dominant strain in the US,” Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, told USA TODAY.

While it is not certain, it can also "drive a US summer surge.”

The CDC warned that a new variant "with substantial capacity to evade immunity from previous infections or vaccines could be associated with seasonal increases in COVID-19 activity.”

In the US, COVID-19 is still linked to roughly 300 to 500 deaths per week, according to recent data based on provisional estimates from the CDC.

Brandon Dionne, an associate clinical professor of pharmacy and health systems sciences at Northeastern University, stated that the virus may evolve and increase the possibility of more severe disease.

“It’s something we definitely want to monitor,” Dionne said. “It could, over time, become the dominant strain in the US, but it’s not yet there," he said.

Also read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

What Is The Cicada COVID Variant?

Cicada was first identified in a respiratory sample in South Africa in November 2024.

It is a descendant of the Omicron BA.3 lineage, and is genetically distinct from the previously circulating JN.1 lineages (including LP.8.1 and XFG).

BA.3.2 comprises two major branches, BA.3.2.1 and BA.3.2.2. BA.3.2.2 also has substitutions like: K356T, A575S, R681H, and R1162P.

The World Health Organization (WHO) has designated BA.3.2 as a Variant Under Monitoring (VUM). It means the variant may not be that dangerous yet, but it may have concerning mutations.

The CDC’s latest Morbidity and Mortality Weekly Report explains that Cicada has “70 to 75 substitutions and deletions in the gene sequence of its spike protein”.

Also read: Maternal Vaccination During Pregnancy Can Prevent COVID-related Hospitalization In Babies: Study

Will Current COVID Vaccines Work?

The variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.

“The number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question,” Dr. Hopkins Jr. said.

However, according to the WHO, current COVID vaccines are expected to continue protecting against severe disease. Moreover, the WHO said BA.3.2 doesn’t seem to be making people sicker so far and hasn’t resulted in increased hospitalizations and deaths.

Common symptoms of Cicada variant include:

• Cough
• Fever or chills
• Sore throat
• Congestion
• Shortness of breath
• Loss of smell or taste
• Fatigue
• Headache.

The Italian authorities this week have confirmed the first human case of H9N2 Avian Flu in the Lombardy region – also the first in the European Union.

The influenza A(H9N2) infection was identified in a traveler returning from a non-European country, where the virus has previously been identified in birds. The patient has coexisting medical conditions and is currently receiving medical treatment in a hospital.

Italy’s Ministry of Health, in a statement, said that they identified “infection with the low-pathogenicity avian influenza A (H9N2) virus of animal origin, in a frail person with concomitant illnesses, who came from a non-European country where he contracted the infection, and is currently hospitalized”.

Public health authorities in the country have performed contact tracing as a precaution to identify and control possible onward transmission and have initiated several epidemiological and microbiological investigations.

“All the required checks were promptly carried out, and the relevant contacts were identified, as part of the ordinary prevention and surveillance activities. Currently, no critical issues have been identified, and the situation is being constantly monitored,” the Ministry said.

What is H9N2?

H9N2 is a subtype of the avian influenza A virus (bird flu) that causes respiratory illness in poultry worldwide and is endemic in many parts of Asia, Africa, and the Middle East.

While low-pathogenic in birds, it sporadically infects humans—usually children—causing mild, influenza-like illness, though severe cases can occur.

According to the WHO, most human cases of infection with avian influenza A(H9N2) viruses are exposed to the virus through contact with infected poultry or contaminated environments.

Also read: Japan Confirms New Highly Pathogenic Bird Flu Outbreak: Report

Human infection tends to result in mild clinical illness. However, globally, there have been some hospitalized cases and two fatal cases reported in the past.

“Based on available information, further sporadic human cases could occur as this virus is one of the most prevalent avian influenza viruses circulating in poultry in different regions. With the currently available evidence, the WHO assesses the current public health risk to the general population posed by this virus as low,” the WHO said.

Human bird flu cases have been reported in countries like China, India, the UK, and Vietnam, often resulting in full recovery.

Also read: UK Reports Its First Human Case Of Bird Flu

Rising Global Bird Flu Cases: Are Humans At Threat

Globally, the spread of bird flu cases has been driven by migratory birds, with increasing outbreaks in poultry farms across Japan, India, South Korea, and the US, among others.

To date, most human cases have occurred in people handling infected poultry or animals.

Key Symptoms of bird flu in humans include:

Cough,

sore throat,

runny or stuffy nose,

difficulty breathing

High fever (often >38°C),

fatigue,

muscle/body aches

Conjunctivitis (red/irritated eyes),

nausea,

vomiting,

diarrhea.

In severe cases, pneumonia and Acute Respiratory Distress Syndrome (ARDS), have been reported.

Human infections remain rare, and the risk is also low, yet scientists say that the virus may someday evolve into a variant that can cause significant harm to humans. Recent infections in mammals (like cattle) increase concern.

Bird flu (H5N1) was detected in the US milk supply, particularly in raw milk from infected dairy cows, with high levels found in milk and udder tissues.

“There is a consensus among those who study how infectious diseases originate and spread that the next pandemic in humans is most likely to originate in a bird flu. Of the different types of bird flu that are especially important, H5N1 avian influenza is considered the most likely candidate for a spillover event, with a high fatality rate,” Dr. Gautam Menon, Professor of Physics & Biology, Ashoka University, told HealthandMe.

“From the small number of infections in humans that have been diagnosed, we know that about 30-40 percent of such cases can be fatal. But we don’t know the possible background of infections in which these deaths or serious cases might occur. In particular, the possibility of asymptomatic infections is open,” he added.